Acadian Asset Management LLC Purchases New Shares in Omnicell, Inc. $OMCL

Key Points

• Acadian Asset Management acquired a new stake in Omnicell, Inc., buying 125,843 shares valued at approximately $4.39 million, representing 0.27% ownership as of the latest SEC filing.
• Recent analyst ratings for OMCL show a variety of price target adjustments, with Piper Sandler lowering its target from $57 to $55 while Wells Fargo increased its target from $37 to $40.
• Omnicell reported a 12-month high of $55.74 and a 12-month low of $22.66, with a current stock price of $31.83, down by 4.4% recently.

Acadian Asset Management LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 125,843 shares of the company's stock, valued at approximately $4,394,000. Acadian Asset Management LLC owned about 0.27% of Omnicell as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Toronto Dominion Bank purchased a new position in shares of Omnicell in the 4th quarter valued at approximately $30,637,000. Pacer Advisors Inc. purchased a new position in shares of Omnicell in the 1st quarter valued at approximately $10,542,000. Nuveen LLC purchased a new position in shares of Omnicell in the 1st quarter valued at approximately $6,218,000. Wellington Management Group LLP raised its position in shares of Omnicell by 52.6% in the 1st quarter. Wellington Management Group LLP now owns 496,680 shares of the company's stock valued at $17,364,000 after purchasing an additional 171,116 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock worth $58,745,000 after buying an additional 154,038 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of Omnicell stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the sale, the executive vice president owned 110,653 shares of the company's stock, valued at approximately $3,679,212.25. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.52% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on OMCL. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Piper Sandler reduced their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded down $0.46 during midday trading on Friday, reaching $31.34. 1,383,338 shares of the stock were exchanged, compared to its average volume of 488,885. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 62.68, a PEG ratio of 6.94 and a beta of 0.82. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74. The firm has a 50-day simple moving average of $30.95 and a two-hundred day simple moving average of $30.89. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. During the same quarter last year, the company earned $0.51 EPS. The business's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.